STOCK TITAN

Highbridge discloses 2.3% Capricor Therapeutics (CAPR) stake via warrants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Highbridge Capital Management, LLC reports beneficial ownership of 1,200,000 shares of Capricor Therapeutics common stock, representing 2.3% of the class. These shares are issuable upon exercise of warrants held by funds it advises.

The 2.3% figure is based on 51,716,975 shares outstanding as of December 5, 2025, after completion of the issuer’s offering and assuming warrant exercise. Highbridge states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Capricor Therapeutics.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The 1,200,000 shares of Common Stock (as defined in Item 2(a)) are issuable upon exercise of warrants reported herein.


SCHEDULE 13G



Highbridge Capital Management, LLC
Signature:/s/ Kirk Rule
Name/Title:Kirk Rule, Executive Director
Date:02/17/2026

FAQ

What ownership stake in Capricor Therapeutics (CAPR) does Highbridge report?

Highbridge Capital Management reports beneficial ownership of 1,200,000 Capricor Therapeutics common shares, representing 2.3% of the class. This percentage is calculated against 51,716,975 shares outstanding as of December 5, 2025, assuming exercise of the reported warrants.

Are Highbridge’s reported CAPR shares currently outstanding or tied to warrants?

The reported 1,200,000 Capricor Therapeutics shares are issuable upon exercise of warrants, not currently outstanding shares. These warrants are directly held by certain funds and accounts advised by Highbridge, which is reporting beneficial ownership on their behalf.

How did Highbridge calculate its 2.3% ownership in Capricor Therapeutics (CAPR)?

Highbridge’s 2.3% ownership is based on 51,716,975 Capricor Therapeutics common shares outstanding as of December 5, 2025. The calculation also assumes full exercise of the 1,200,000-share warrant position held by the Highbridge-advised funds.

Does Highbridge’s filing indicate an attempt to control Capricor Therapeutics (CAPR)?

Highbridge explicitly certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Capricor Therapeutics, nor in connection with any transaction having that control-related purpose or effect.

Who has the economic rights to the CAPR shares reported by Highbridge?

The economic rights to the reported Capricor Therapeutics shares reside with the Highbridge Funds. These funds have the right to receive dividends or sale proceeds, while Highbridge Capital Management reports beneficial ownership as the investment adviser to those funds and accounts.

Why does Highbridge note ownership of 5 percent or less of CAPR’s common stock?

The filing states ownership of 5 percent or less of Capricor Therapeutics’ common stock. With a 2.3% reported stake, this confirms Highbridge’s position is below major-holder thresholds typically associated with larger influence or control considerations.
Capricor Therapeutics Inc

NASDAQ:CAPR

CAPR Rankings

CAPR Latest News

CAPR Latest SEC Filings

CAPR Stock Data

1.25B
44.04M
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN DIEGO